Francesco Bertoni

This study identifies OSTM1 as a tumor suppressor in B-cell malignancies by showing it activates the cAMP/PKA/CREB pathway through ubiquitin E3 ligase activity.

This study identifies DDX21 as a key effector of ETS1/FLI1 in ABC-DLBCL, linking it to cell cycle, immune evasion, and snoRNA processing, with potential therapeutic implications.

This study identifies IL-16 production as a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas, showing that targeting the IL-16/CD9 axis restores drug sensitivity.

The paper shows ibrutinib increases CD19 expression in B-cell lymphoma models, improving the effectiveness of CD19-CAR T cells.

This study identifies multiple resistance mechanisms to ETS-targeting agents in DLBCL and suggests combination therapies with BCL2, MCL1, and XPO1 inhibitors.

This study evaluates the antitumor activity of seven natural antimicrobial peptides against MZL cell lines and resistant derivatives, finding W-trematocine and temporin L show potent cytotoxicity with low toxicity to non-malignant cells.

This paper shows that CDK9 inhibitor PRT2527 kills marginal zone lymphoma cells, even those resistant to other drugs, and enhances the effects of BTK, PI3K, and BCL2 inhibitors.

This study shows that combining infigratinib with BTK/PI3K inhibitors or bendamustine improves efficacy in lymphoma cell models, reversing resistance and suggesting FGFR inhibition as a therapeutic strategy.

This study evaluates the preclinical efficacy of BGB-16673 and sonrotoclax in marginal zone lymphoma models, showing enhanced apoptosis when combined.

The paper characterizes ROR1 expression in B-cell lymphoma models and shows that ROR1-positive models are sensitive to a ROR1-targeting ADC.

This study identifies PLK1 inhibition as a strategy to enhance BTK blockade in MZL by overcoming resistance through transcriptomic and mechanistic analysis.

This paper evaluates the effectiveness of 177Lu-lilotomab satetraxetan in lymphoma cell lines, showing it is more effective in CD37-positive B-cell lymphomas and identifies potential biomarkers and synergistic combinations.

This study shows that combining CXCR4 inhibitors with standard and targeted therapies improves anti-tumor effects in B-cell lymphoma models, especially in drug-resistant cases.

This study evaluates KAT/3BP, a 3BP derivative, showing in vitro and in vivo anti-tumor activity against lymphoma models, including resistant cell lines and synergistic effects with existing therapies.

EasyCircR detects and reconstructs circRNA-miRNA-mRNA regulatory networks through post-transcriptional analysis and visualization.

This paper develops a 3D co-culture system using bone marrow stromal cells to study drug resistance in B cell non-Hodgkin lymphoma and identifies potential resistance mediators.

This paper identifies ADARreg, an elncRNA that modulates BCR signaling and immune evasion in lymphoma by altering RNA stability, localization, and editing, providing a potential therapeutic target.

This paper identifies two resistance mechanisms to the CD37-targeting ADC naratuximab emtansine in lymphoma cell lines and suggests combination therapies to overcome resistance.

This study identifies HERV-K as a therapeutic target in DLBCL, develops a humanized nanobody with anti-lymphoma activity, and shows its potential through antibody-dependent cytotoxicity.

The paper applies a prize-collecting Steiner tree method to select a gene signature for classifying diffuse large B-cell lymphoma subtypes, outperforming existing methods.

OmicsNet integrates multi-omics data using multilayer networks to identify pathways linking genotypes to phenotypes, enabling functional analysis and drug response prediction.